Mallika Lala

1.3k total citations · 1 hit paper
25 papers, 936 citations indexed

About

Mallika Lala is a scholar working on Oncology, Pharmacology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mallika Lala has authored 25 papers receiving a total of 936 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Pharmacology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mallika Lala's work include Cancer Immunotherapy and Biomarkers (13 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and CAR-T cell therapy research (6 papers). Mallika Lala is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Antibiotics Pharmacokinetics and Efficacy (7 papers) and CAR-T cell therapy research (6 papers). Mallika Lala collaborates with scholars based in United States, South Africa and Spain. Mallika Lala's co-authors include Kapil Mayawala, Elliot Chartash, Jogarao Gobburu, Vassiliki Karantza, Lokesh Jain, Gursel Aktan, Yaning Wang, Pravin Jadhav, Matthew L. Rizk and Vikram Sinha and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Mallika Lala

22 papers receiving 924 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

2021 196 citations Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology profile →

Peers

Countries citing papers authored by Mallika Lala

Since Specialization

Citations

This map shows the geographic impact of Mallika Lala's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mallika Lala with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mallika Lala more than expected).

Fields of papers citing papers by Mallika Lala

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mallika Lala. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mallika Lala. The network helps show where Mallika Lala may publish in the future.

Co-authorship network of co-authors of Mallika Lala

This figure shows the co-authorship network connecting the top 25 collaborators of Mallika Lala. A scholar is included among the top collaborators of Mallika Lala based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mallika Lala. Mallika Lala is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial 2025 ·Annals of Oncology ·(unknown), (unknown), (unknown), (unknown), Ignacio Casarini, Tibor Csőszi, Mehmet Alı Nahıt Şendur, José Diogo Martins, Antonio Calles, (unknown), Min Wang, (unknown), Hiroshige Yoshioka, Suresh Nair, Xiaoyu Song, Xiaoyan Deng, Mallika Lala, (unknown), Toshiaki Takahashi	4
2	Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma 2025 ·Cancer Research ·(unknown), Richard Khanyile, Graham Cohen, (unknown), Chloe Walton, (unknown), Bernardo L. Rapoport, Christian Caglevic, Patricio Yañez, Mallika Lala, Gina Song, Julia W. Cohen, Carlos A. Rojas	1
3	Abstract CT036: Bioavailability of MK-3475A (pembrolizumab with berahyaluronidase alfa; “subcutaneous pembrolizumab”) in participants with advanced or metastatic solid tumors 2025 ·Cancer Research ·Òscar Reig, Graham Cohen, Byoung Chul Cho, Carlos A. Rojas, C. Walton, (unknown), Richard Khanyile, Zsuzsanna Pápai, Mallika Lala, Gina Song, (unknown), (unknown)	1
4	Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study 2024 ·PLoS ONE ·Graham Cohen, Bernardo L. Rapoport, (unknown), Paul Ruff, Ana Arance, (unknown), Baerin Houghton, Michael P. Brown, (unknown), Eva Muñoz‐Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, (unknown), Elliot Chartash, Conrad Jacobs	0
5	168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC) 2021 ·Annals of Oncology ·Balázs Halmos, Patrick Cobb, Melissa L. Johnson, Lokesh Jain, (unknown), Sanatan Saraf, Mallika Lala, Takayasu Kurata	0
6	First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ breakdown → 2021 ·Annals of Oncology ·Jiaxin Niu, Corinne Maurice‐Dror, D.H. Lee, D.-W. Kim, Adnan Nagrial, Mark Voskoboynik, Hyun Cheol Chung, Kathryn F. Mileham, Ulka N. Vaishampayan, Drew Rasco, Talia Golan, Todd M. Bauer, Antonio Jimeno, Vincent Chung, Elliot Chartash, Mallika Lala, (unknown), Jane Healy, Myung‐Ju Ahn	196
7	Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma 2021 ·Cancer Research ·Conrad Jacobs, Bernardo L. Rapoport, Graham Cohen, Mallika Lala, (unknown), Pavan Vaddady, Ferdous Gheyas, Dinesh de Alwis, Vikram Sinha, (unknown), Elliot Chartash, Lokesh Jain	8
8	Pivotal Dose of Pembrolizumab: A Dose‐Finding Strategy for Immuno‐Oncology 2021 ·Clinical Pharmacology & Therapeutics ·(unknown), Manash Chatterjee, Mallika Lala, Anson K. Abraham, Tomoko Freshwater, Lokesh Jain, Vikram Sinha, Dinesh P. de Alwis, Kapil Mayawala	20
9	KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma. 2021 ·Journal of Clinical Oncology ·Conrad Jacobs, Bernardo L. Rapoport, (unknown), Paul Ruff, Ana Arance, (unknown), James R. Anderson, Mallika Lala, Lokesh Jain, (unknown), Elliot Chartash, Graham Cohen	11
10	Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants 2020 ·Clinical Pharmacology in Drug Development ·(unknown), Yang Liu, (unknown), Terry O’Reilly, Francheska Colón‐González, Evan Friedman, Mallika Lala, Elizabeth G. Rhee, Matthew L. Rizk	3
11	A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation 2020 ·European Journal of Cancer ·Mallika Lala, Tommy Li, Dinesh P. de Alwis, Vikram Sinha, Kapil Mayawala, Noboru Yamamoto, Lillian L. Siu, Elliot Chartash, (unknown), Lokesh Jain	106
12	Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review 2019 ·Breast Cancer Research ·(unknown), Vassiliki Karantza, Gursel Aktan, Mallika Lala	94
13	Immunogenicity of pembrolizumab in patients with advanced tumors 2019 ·Journal for ImmunoTherapy of Cancer ·(unknown), Julie A. Stone, (unknown), Ellen Snyder, Leslie Lipka, David C. Turner, Anne Chain, Mallika Lala, Mengyao Li, Seth Robey, Anna Kondic, Dinesh de Alwis, Kapil Mayawala, Lokesh Jain, Tomoko Freshwater	44
14	Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections 2019 ·CPT Pharmacometrics & Systems Pharmacology ·(unknown), Parul Patel, Mallika Lala, Kenny J. Watson, William Copalu, Ming Xu, (unknown), Katherine Young, Matthew L. Rizk	45
15	Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review 2018 ·Oral Oncology ·Mallika Lala, Diana Chirovsky, Jonathan D. Cheng, Kapil Mayawala	62
16	Simplification of Imipenem Dosing by Removal of Weight‐Based Adjustments 2018 ·The Journal of Clinical Pharmacology ·Mallika Lala, Michelle Brown, Bhavna Kantesaria, (unknown), Amanda Paschke, Matthew L. Rizk	4
17	A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation. 2018 ·Journal of Clinical Oncology ·Mallika Lala, Mengyao Li, Vikram Sinha, Dinesh de Alwis, Elliot Chartash, Lokesh Jain	26
18	Genetics-Based Pediatric Warfarin Dosage Regimen Derived Using Pharmacometric Bridging 2013 ·The Journal of Pediatric Pharmacology and Therapeutics ·Mallika Lala, Gilbert J. Burckart, Cheryl Takao, Vera Pravica, Jeremiah D. Momper, Jogarao Gobburu	14
19	Clarification on Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetic Studies 2011 ·The Journal of Clinical Pharmacology ·Yaning Wang, Pravin Jadhav, Mallika Lala, Jogarao Gobburu	89
20	Application of Pharmacometric Methods to Improve Pediatric Drug Development 2011 ·VCU Scholars Compass (Virginia Commonwealth University) ·Mallika Lala	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact